As the government struggles to ramp up the production of Covid shots to meet its target of vaccinating all adults by the year-end, the supply of Bharat Biotech's Covaxin has been slowed down by "quality issues" at the company's newest facility in Bengaluru, one of the government's top advisers has said. In an exclusive interview to NDTV, Covid task force member NK Arora admitted that the government was banking on a much sharper rise in the production of Covaxin – one of the two main vaccines in use in India – but was set back because of the quality issues at what is the company's biggest plant globally.
